Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1272671 | 0.85 | — | — | |
| Sulfuric Acid SCHEMBL6049589 | 0.79 | ALOX15 (0.47) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| Sulfuric Acid SCHEMBL30423558 | 0.79 | KDM4E (0.33) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| Sulfuric Acid SCHEMBL11815400 | 0.79 | ALOX15 (0.47) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| Sulfuric Acid SCHEMBL8671837 | 0.77 | ALOX15 (0.46) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| SCHEMBL2893660 | 0.73 | ALDH1A1 (0.40) | ALDH1A1CYP3A4MMP1MMP2MMP3 | |
| SCHEMBL13973081 | 0.72 | — | — | |
| SCHEMBL11979596 | 0.72 | — | — | |
| SCHEMBL11789491 | 0.72 | EGLN1 (0.42) | KDM4EBLMALDH1A1CYP3A4MMP1 | |
| SCHEMBL4092758 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143151-A | Formula and process of methyl pyrimidine phosphorus | 海利贵溪新材料科技有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-116510525-B | High-flux nanofiltration membrane based on guanidino compound and preparation method and application thereof | 天津大学 | 2023-09-01 | — | — | CN | claimed |
| CN-116510525-A | High-flux nanofiltration membrane based on guanidino compound and preparation method and application thereof | 天津大学 | 2023-08-01 | — | — | CN | claimed |
| CN-111019121-A | Preparation method of guanidine polymer ionic liquid | 石家庄学院 | 2020-04-17 | — | — | CN | claimed |
| CN-110804198-A | Preparation method of antibacterial cellulose degradable composite membrane | 石家庄学院 | 2020-02-18 | — | — | CN | claimed |
| CN-110804179-A | High-molecular ionic liquid with good film forming property and long-term antibacterial activity and application thereof | 石家庄学院 | 2020-02-18 | — | — | CN | claimed |
| CN-118496627-B | FRP composite material and preparation method and application thereof | 南京斯贝尔复合材料仪征有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118496627-A | FRP composite material and preparation method and application thereof | 南京斯贝尔复合材料仪征有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240218344-A1 | LIQUID THROMBIN REAGENT | INSTRUMENTATION LABORATORY COMPANY | 2024-07-04 | — | — | US | disclosed |
| EP-4389140-A1 | LIQUID THROMBIN REAGENT CONTAINING GUANIDINE DERIVATIVES | Instrumentation Laboratory Company (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118240806-A | Liquid thrombin reagent | 仪器实验室公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-114072378-B | Process (III) for preparing metastable crystal modifications of N- (aminoiminomethyl) -2-glycine | 澳泽化学特罗斯特贝格有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117143151-A | Formula and process of methyl pyrimidine phosphorus | 海利贵溪新材料科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20070021555-A1 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2007008563-A2 | PREPARATION OF PEGYLATED CONJUGATES OF VLA-4 ANTAGONISTS VIA A MITSUNOBU' S REACTION | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006127584-A1 | IMIDAZOLONE PHENYLALANINE DERIVATIVES AS VLA-4 ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006010054-A2 | MULTIVALENT VLA-4 ANTAGONISTS COMPRISING POLYETHYLENE GLYCOL MOIETIES | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060013799-A1 | Multimeric VLA-4 antagonists comprising polymer moieties | ELAN PHARMACEUTICAL INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005111020-A2 | PYRIMIDINE HYDANTOIN ANALOGUES WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050261324-A1 | Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060013799-A1 | Multimeric VLA-4 antagonists comprising polymer moieties | VCAM1, ICAM1, ITGB4 | KDM4E 2479/4885CYP2D6 3513/4885CYP2C19 3900/4885 |
| US-20050261324-A1 | Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, LPAR4 | KDM4E 3533/4885CYP2D6 2596/4885CYP2C19 4064/4885 |
| US-20240218344-A1 | LIQUID THROMBIN REAGENT | TFPI, F2, PLG | KDM4E 600/4885CYP2D6 1025/4885CYP2C19 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.